January 9, 2008
Relypsa appoints Ronald A. Krasnow Senior Vice President, Intellectual Property and Chief Patent Counsel.

October 29, 2007
Relypsa formed with $33 Million Series A Funding to discover and develop polymeric drugs.

Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in cardiovascular and renal disease.  The new company is a spin-out of Ilypsa, Inc., a wholly-owned subsidiary of Amgen Inc. (acquired by Amgen in July 2007 for $ 420 M). Relypsa commences operations with rights to a proprietary drug discovery platform and a pipeline of product candidates including a potassium binder drug candidate for the treatment of hyperkalemia, known as RLY5016, as well as a novel sodium binder, RLY102, for the potential treatment of congestive heart failure.  Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform.

Our Investors

5AM Ventures

Amgen

Delphi Ventures

Mediphase Ventures

New Leaf Venture